If you’ve spent any time researching longevity, you’ve run into NAD+. The pitch is consistent: restore youthful energy, protect DNA, slow aging. And the premise is genuinely backed by science — NAD+ is one of the most fundamental molecules in human biology, and it does decline significantly with age.

What gets far less airtime is a practical question that changes what you should actually do about it: how does NAD+ get into your cells in the first place?

The answer has real clinical implications — and it’s the difference between an informed protocol and a very expensive wellness trend.

What NAD+ actually does in the cell

Nicotinamide adenine dinucleotide (NAD+) is not a supplement trend. It is a coenzyme present in every living cell, and it has a hand in several of the most critical processes keeping you alive:

Mitochondrial energy production (ATP synthesis). NAD+ is a core electron carrier in the electron transport chain. Without adequate NAD+, your mitochondria cannot produce ATP efficiently — which means every energy-dependent function in your body feels it.
DNA repair. PARP enzymes, which patch breaks in your DNA before they become permanent mutations, are NAD+-dependent. They consume NAD+ rapidly during active repair.
Sirtuin activation. Sirtuins — the “longevity proteins” — are NAD+-dependent deacetylases. They regulate gene expression, metabolic efficiency, and cellular stress responses. SIRT1 and SIRT3 in particular are tied closely to metabolic health and mitochondrial quality control.
Cellular signaling and inflammation. CD38, an enzyme that degrades NAD+ as part of the immune response, becomes more active with age — one of the main reasons NAD+ levels fall even when diet and exercise are dialed in.

NAD+ levels in human tissue fall roughly 50 percent between young adulthood and midlife, and continue declining. That decline correlates with reduced mitochondrial function, impaired DNA repair capacity, and diminished sirtuin activity — all things that show up in how people feel, perform, and age.

The part most NAD+ marketing skips

Here is where the biology gets inconvenient for certain business models.

The NAD+ molecule is large, negatively charged, and hydrophilic. That combination means it does not cross the cell membrane efficiently on its own. Cells do not simply absorb intact NAD+ from the bloodstream and use it directly. The primary mechanism by which cells actually raise intracellular NAD+ is the salvage pathway — a series of enzymatic steps that take up smaller precursor molecules, convert them inside the cell, and reconstruct NAD+ where it needs to be.

This is not a fringe view. It is the consensus in NAD+ biochemistry, and it is why the most productive research into how to increase NAD+ in tissue has focused not on NAD+ itself but on what feeds the salvage pathway: precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN).

What about IV NAD+ drips?

Intravenous NAD+ has become a fixture at wellness clinics, and there are real reasons it can produce noticeable effects — so this deserves a straight answer rather than a dismissal.

Delivering NAD+ intravenously gets a large amount of the molecule into systemic circulation quickly. Some of that circulating NAD+ is hydrolyzed extracellularly into precursor forms (including NMN and nicotinamide) that can be taken up by cells and fed into the salvage pathway. Some effects may also arise from extracellular NAD+ acting on purinergic receptors on cell surfaces. And for people who are severely depleted, flooding the system may move the needle.

But there is a practical problem that anyone who has sat through a fast NAD+ drip knows well: the infusion itself can produce intense flushing, chest tightness, palpitations, and nausea. Those effects are rate- and dose-dependent — they reflect a large bolus of NAD+ entering systemic circulation faster than the body can process it. Slowing the infusion rate substantially reduces discomfort, but it also extends the time commitment to four or more hours.

The discomfort is not evidence that “the NAD+ can’t get into cells and is backing up.” It is a pharmacokinetic consequence of systemic flooding at high infusion rates. The more precise observation is that much of a large IV NAD+ dose is metabolized extracellularly anyway — which raises a legitimate clinical question about whether delivering the precursor directly, either orally or intravenously, is a more efficient route to the intracellular NAD+ you’re actually trying to raise.

That is exactly what precursor-based protocols are designed to do.

NR and NMN: how the salvage pathway works for you

NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are both downstream precursors in the NAD+ biosynthesis pathway, sitting one or two steps from NAD+ itself.

NMN is taken up by cells via specific transporters (the Slc12a8 transporter in gut and other tissues) and converted intracellularly to NAD+ by NMNAT enzymes.
NR crosses into cells and is phosphorylated to NMN, then proceeds to NAD+ through the same pathway.

Human clinical trials — including work from the Brenner lab (which discovered NR’s role in NAD+ metabolism), David Sinclair’s group at Harvard, and several independent investigators — suggest that both NR and NMN may support meaningful increases in blood and tissue NAD+ levels at doses studied. The evidence base is still growing, and the translation from “elevated NAD+ in blood” to specific clinical outcomes (muscle function, cognitive sharpness, metabolic efficiency) is promising but not yet settled science. Honest framing matters here: these are supplements with a strong mechanistic rationale and an accumulating clinical signal, not approved drugs with proven endpoints.

A word on regulatory status: NMN’s regulatory standing as a dietary supplement in the United States has been contested. In 2022 the FDA concluded that because NMN had been investigated as a new drug prior to being marketed as a supplement, it could not be marketed as a dietary supplement under DSHEA without further regulatory action. As of this writing that status remains evolving — some manufacturers continue to sell NMN supplements while the regulatory situation develops. NR, by contrast, has received multiple GRAS (Generally Recognized As Safe) notices and a more settled supplement classification. Any physician-directed protocol should account for current regulatory status; this is another reason a clinical rather than a self-directed approach matters.

The case for precursor-based IV therapy

Here is where the two ideas — IV delivery and precursor biochemistry — come together.

If the goal is to raise intracellular NAD+ quickly, with the absorptive efficiency of IV delivery and the cellular uptake advantage of precursor form, precursor-based IV infusions are a logical synthesis. Delivering NMN or NR intravenously bypasses gastrointestinal variation in oral absorption and puts high concentrations of bioavailable precursor into circulation for rapid cellular uptake via the salvage pathway — without the rate-dependent discomfort profile of high-dose intact NAD+ drips.

This is not theoretical. It reflects how precision clinics that have moved past the early NAD+ drip model now structure IV therapy when the clinical goal is meaningful, measurable cellular NAD+ repletion rather than an acute wellness experience.

What physician-directed NAD+ support looks like

The distinction that matters most is between a one-size-fits-all spa drip and a protocol that actually starts with your biology.

At Longitude Life, NAD+ repletion is part of our Life Extension Protocols — meaning it fits into a broader picture, not a standalone infusion. The process looks like this:

Baseline biomarkers. We assess NAD+ metabolite levels (via blood or urine metabolomics), alongside mitochondrial health markers, inflammatory status (CD38 activity is a known NAD+ consumer), and metabolic function. See Comprehensive Diagnostics for what that picture includes.
Protocol design. Oral NR or NMN, precursor-based IV, or a combination — selected by your baseline, your goals, and the pace of repletion that’s appropriate for you.
Dose calibration. Dosing in published human trials has ranged from 250 mg to 2,000 mg daily depending on the compound, the endpoint, and the individual. There is no universal correct dose, and dosing without labs is guessing.
Follow-up tracking. NAD+ metabolite levels are re-measured to confirm the protocol is working and adjusted if needed. This is the part missing from every spa drip — not just the initial measurement, but the feedback loop.

The difference between that and an unmonitored supplement or a fast IV drip is exactly the difference between a clinical tool and a wellness trend.

Who this is for

NAD+ support tends to make the most sense for people experiencing energy decline, early metabolic changes, or reduced recovery capacity that doesn’t fully resolve with optimized sleep, training, and nutrition — particularly when biomarker data suggests mitochondrial or metabolic insufficiency. It is not a replacement for those fundamentals, and it is not appropriate for everyone. Certain conditions, medications, and individual metabolic profiles affect how NAD+ precursors are handled; a physician review is the appropriate starting point.

Frequently asked questions

Is NAD IV therapy worth it? It depends on what you are getting and how it is administered. A fast high-dose NAD+ drip can be uncomfortable and much of the intact NAD+ is broken down extracellularly before reaching cells anyway. A slower, more carefully dosed infusion — or a precursor-based IV delivering NR or NMN directly — may offer better cellular uptake with less discomfort. The most important variable is whether the protocol is matched to your actual biomarker picture rather than a standard wellness package.

NMN vs NR — which is better? Both are legitimate precursors that feed the NAD+ salvage pathway and may raise intracellular NAD+. NMN is one step closer to NAD+ biochemically; NR has a more established supplement regulatory history in the US (NMN’s status under DSHEA is evolving). Human data for both is promising but still accumulating. A physician can recommend one or both based on your labs, your goals, and current regulatory considerations for your situation.

Can you take NAD orally? Yes — oral NR and NMN are the most common forms and have shown the ability to raise blood NAD+ metabolite levels in human trials. Oral bioavailability varies between individuals, which is why some protocols use IV delivery to bypass gastrointestinal variability and achieve faster repletion. Intact oral NAD+ supplements also exist but face the same membrane-crossing challenge as IV NAD+; precursor forms are generally considered more efficient.

How to increase NAD naturally? Several lifestyle factors support endogenous NAD+ production and reduce its consumption: fasting and caloric restriction activate AMPK pathways that upregulate NAD+ synthesis; resistance exercise may support SIRT1 and NAD+ recycling; reducing chronic inflammatory load decreases CD38-driven NAD+ consumption. Tryptophan from dietary protein is also a de-novo NAD+ precursor via the kynurenine pathway. These are genuine levers — and they are what a comprehensive protocol addresses alongside supplementation, not instead of it.

Does NAD+ really reverse aging? “Reverse aging” is a claim the science does not currently support in humans. What the research does suggest is that declining NAD+ is a meaningful contributor to the metabolic and cellular changes that accumulate with age, and that restoring NAD+ levels toward youthful ranges may support mitochondrial function, DNA repair capacity, and sirtuin activity. Whether that translates to measurable longevity benefits in humans — rather than in model organisms — is an active area of research. Honest medicine is precise about that distinction.

The bottom line

NAD+ matters. The decline is real, the mechanisms are well-established, and the tools to address it are better than they were even five years ago. What the wellness industry tends to understate is that how you raise intracellular NAD+ matters as much as that you try to raise it — and the most efficient path runs through the salvage pathway, via precursors, rather than through direct high-dose NAD+ flooding.

If your energy, recovery, or metabolic biomarkers suggest your cells aren’t running at full capacity, a conversation with a physician — one who will actually look at your labs before recommending a protocol — is the right starting point.

Explore Life Extension Protocols at Longitude Life →

This article is for educational purposes and is not medical advice. NAD+ precursor therapies are sold as dietary supplements; NMN’s regulatory status as a supplement in the United States remains subject to FDA review. Any therapy should be undertaken only after evaluation by a qualified physician.

NAD+ and Why Precursors (NR/NMN) Are the Smarter Way to Raise Cellular Energy